Prolonged effects of short‐term anti‐CD20 B cell depletion therapy in murine systemic lupus erythematosus
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Objective: Although B cells are implicated in the pathogenesis of systemic lupus erythematosus, the role of B cell depletion (BCD) as a treatment is controversial, given the variable benefit in human disease. This study was undertaken to test the effects of BCD therapy in a murine lupus model to better understand the mechanisms, heterogeneity, and effects on disease outcomes. Methods: (NZB × NZW)F 1 female mice with varying degrees of disease severity were treated with an anti‐mouse CD20 (anti‐mCD20) antibody (IgG2a), BR3‐Fc fusion protein (for BAFF blockade), or control anti‐human CD20 monoclonal antibody (∼10 mg/kg each). Tissue samples were harvested and analyzed by flow cytometry. The development and extent of nephritis were assessed by monitoring proteinuria (using a urine dipstick) and by immunohistochemical analysis of the kidneys. Serum immunoglobulin levels were measured by enzyme‐linked immunosorbent assay. Results: After a single injection of anti‐mCD20, BCD was more efficient in the peripheral blood, lymph nodes, and spleen compared with the bone marrow and peritoneum of normal mice as well as younger mice with lupus. Since depletion of the marginal zone and peritoneal B cells was incomplete and variable, particularly in older mice with established nephritis, a strategy of sequential weekly dosing was subsequently used, which improved the extent of depletion. BAFF blockade further enhanced depletion in the spleen and lymph nodes. Early BCD therapy delayed disease onset, whereas BCD therapy in mice with advanced disease reduced the progression of nephritis. These effects were long‐lasting, even after B cell reconstitution occurred, and were associated with a reduction in T cell activation but no significant change in autoantibody production. Conclusion: The lasting benefit of a short course of BCD therapy in lupus‐prone mice with an intact immune system and established disease highlights the validity of this treatment approach.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
B cells regulate autoimmunity by provision of IL-10
Fillatreau, S., Sweenie, C. H., McGeachy, M. J., Gray, D., & Anderton, S. M. (2002) · Nature Immunology · doi:10.1038/ni833 · Cited by 1,647
Cytokine-producing B lymphocytes-key regulators of immunity
Lund, F. E. (2008) · Current Opinion in Immunology · doi:10.1016/j.coi.2008.03.003 · Cited by 556
Cited by
The Pathogenesis of Lupus Nephritis
Lech, M., & Anders, H.-J. (2013) · Journal of the American Society of Nephrology · doi:10.1681/asn.2013010026 · Cited by 496
Kansal, R., Richardson, N., Neeli, I., Khawaja, S., Chamberlain, D., Ghani, M., Ghani, Q.-U.-A., Balazs, L., Beranova-Giorgianni, S., Giorgianni, F., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aav1648 · Cited by 382
The pathogenesis of systemic lupus erythematosus—an update
Choi, J., Kim, S. T., & Craft, J. (2012) · Current Opinion in Immunology · doi:10.1016/j.coi.2012.10.004 · Cited by 360
Redefining lupus nephritis: clinical implications of pathophysiologic subtypes
Yu, F., Haas, M., Glassock, R., & Zhao, M.-H. (2017) · Nature Reviews Nephrology · doi:10.1038/nrneph.2017.85 · Cited by 340
Ichikawa, H. T., Conley, T., Muchamuel, T., Jiang, J., Lee, S., Owen, T., Barnard, J., Nevarez, S., Goldman, B. I., Kirk, C. J., et al. (2012) · Arthritis & Rheumatism · doi:10.1002/art.33333 · Cited by 244
“Serum from proteasome inhibitor–treated blood samples was collected and frozen prior to quantifying total IgG antibody levels as previously described (20).”
InfluentialSelf-citation
Metadata
- Authors
- Bekar, K. W., Owen, T., Dunn, R., Ichikawa, T., Wang, W., Wang, R., Barnard, J., Brady, S., Nevarez, S., Goldman, B. I., Kehry, M., & Anolik, J. H.
- Venue
- Arthritis & Rheumatism
- Publisher
- Wiley
- Published
- 2010-08
- Volume
- 62
- Issue
- 8
- Pages
- 2443-2457
- ISSN
- 0004-3591 (ISSN-L)
- 1529-0131
- OpenAlex
- W1993290536
- Cited by
- 100
- References
- 2
- FWCI
- 4.62
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.